ABSTRACT BACKGROUND The risk of recurrent ischemic and bleeding events after primary percutaneous coronary intervention
P atients with ST-segment elevation myocardial infarction (STEMI) who are undergoing primary percutaneous coronary intervention (PCI) are at high risk for ischemic and bleeding events, both of which strongly affect subsequent morbidity and mortality (1) (2) (3) (4) . The selection of optimal antithrombotic agents in the acute and chronic phases after STEMI, in terms of their potency and duration, requires a careful evaluation of the offsetting risks of ischemia and bleeding (5) (6) (7) . Although the predictors and impact of ischemic and hemorrhagic events after primary PCI in STEMI have been investigated (1, 2) , their absolute and relative rates over time remain uncertain. In this regard the risk for recurrent ischemic and bleeding events may not be uniform over time, a consideration that may influence the benefit-to-risk ratio of guideline-recommended antithrombotic therapies.
For example, because the highest rate of ischemic events occurs in the first few days or weeks after STEMI (8, 9) , a strategy of potent platelet inhibition could be considered during the first month after the patient's presentation, if the bleeding risk is not excessive in this period. Thereafter, down-titrating to a less potent regimen could offer a favorable balance of ischemic protection versus bleeding avoidance. Such considerations rely on understanding the relative risks of ischemia and bleeding in different risk periods.
All adverse outcomes (including recurrent events) must be considered for the true burden of ischemic and bleeding complications to be fully appreciated.
However, conventional time-to-event analyses censor patients after the first endpoint event is experienced, thereby masking subsequent recurrent adverse events, reducing statistical power, and diminishing appreciation for the potential benefit (or harm) of preventative therapies (10) . We therefore determined the average daily rate (ADR) of all ischemic and bleeding events in the first year after primary PCI in patients enrolled in the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial, to characterize the total and temporal-related burden of adverse outcomes after STEMI.
METHODS
STUDY DESIGN AND OBJECTIVES. The study design of the HORIZONS-AMI trial has been previously described (11, 12) . Briefly, The objectives of the present study were as follows: 1) to determine the average daily ischemic rate (ADIR) and average daily bleeding rate (ADBR) within different time intervals and overall within the first year following primary PCI for STEMI (the time period for which aspirin and clopidogrel were prescribed for all patients); 2) to examine the extent to which recurrent events contributed to the total burden of adverse outcomes; and 3) to determine whether randomized intraprocedural antithrombotic treatment (bivalirudin monotherapy vs. UFH plus GPI) affected these relative and absolute rates.
HORIZONS
ENDPOINT AND TIME INTERVAL DEFINITIONS. ADIR events were defined as cardiac death, myocardial infarction (MI), and definite stent thrombosis (ST). ADBR events were defined as Thrombolysis In Myocardial Infarction artery bypass graft (CABG) procedures. The definition of MI in the periprocedural and nonprocedural periods has been previously described (9, 10) . ST was defined according to the Academic Research Consortium criteria (13) . Net adverse clinical events were defined as death, MI, definite ST, and TIMI major and minor bleeding. The ADRs for ischemic and bleeding events were categorized according to the timing of their occurrence in the following time intervals: acute phase (#24 h), subacute phase (day 1 to day 30), early phase (0 to 30 days), and late phase (day 30 to day 365). To account for the sometimes delayed recognition and diagnosis of bleeding events, ADRs were also examined using an alternative cutoff between the acute and the subacute phases, specifically: day 0 to day 3 (modified acute phase) and day 3 to day 30 (modified subacute phase). A clinical events committee blinded to treatment group allocation independently adjudicated all endpoint events through original source document evaluation. Giustino et al. Table 1) . Conversely, most ischemic and bleeding events were not temporally related ( Table 2) . Table 1 ). The ADIR and ADBR in the acute, subacute, early and late phases are shown in Figure 3 , Table 3 , Figure 3A ) and ADBR (Table 4, Figure 3B ) were observed as the patients transitioned from the acute to the subacute to the late period (p < 0.0001 for both ADIR and ADBR, across all time intervals). Results were consistent in the modified acute and subacute intervals (Online Table 4 ). The daily rates for ischemic and bleeding events are shown in Online Figure 2 . Values are the number of recurrent events/number of primary bleeding or ischemic events (%). Proportion of ischemic and bleeding events occurring within 365 days following a bleeding (upper rows) or ischemic event (lower row), respectively. Figure 1 . 1.51%; 95% CI: 1.04% to 1.98%; p < 0.0001). Results were consistent after excluding cardiac death from the composite ischemic endpoint (Online Figure 4) .
AVERAGE DAILY ISCHEMIC AND BLEEDING RATES
ACCORDING TO THE ANTITHROMBOTIC TREATMENT.
Differences in ADRs between bivalirudin-treated and UFH plus GPI-treated patients are illustrated in
Online Table 5 (using a cutoff of #24 h for the acute phase) and Online Table 6 (using a cutoff of #3 days for the acute phase). At 30 days, bivalirudin was associated with lower rates of bleeding and mortality, with no significant differences observed in ADIR.
Conversely, there were no significant differences in in trials of heart failure therapies, as many as 50% of heart failure re-hospitalizations are recurrent events occurring in single participants (16, 17) . Application of time-to-first-event analysis for such endpoints results in a substantial loss of information and statistical power (18) . In the present study, we examined the daily risk of discrete first-time and recurrent ischemic and bleeding events over 1 year after primary PCI for
STEMI. Approximately 21% of all ischemic events and 16% of all bleeding events occurring within 1 year were recurrent events. Moreover, by detailed chart review we examined the interrelationship of ischemic and bleeding events. For example, it could be envisioned that many episodes of major bleeding during follow-up arise from PCI treatment of ischemic complications (e.g., ST) or that many ischemic events arise after discontinuation of antiplatelet agents or other therapies to treat major bleeding. However, in contrast to this expectation, only a few adverse ischemic and bleeding events were temporally related to bleeding and ischemic events, respectively. These findings place into perspective the total burden of adverse events that occur within the first year after primary PCI for STEMI (in patients treated with a dual antiplatelet regimen of aspirin and clopidogrel), and emphasize the relative independence of ischemic and bleeding complications in these high-risk patients.
The absolute risk for ischemic events was highest early after the PCI procedure, and then it exponentially decayed over time. This finding emphasizes that the early period (especially the first few days after primary PCI) is the interval in which more potent antiplatelet agents may have the greatest utility in improving prognosis. However, the absolute rate of bleeding was also greatest in this early period, and as such more potent agents may also produce harm in this interval. Such a trade-off is evidenced by procedural anticoagulation with bivalirudin rather than UFH plus GPI, which in the first 24 h results in greater rates of ST but less major bleeding. These offsetting risks can be favorably affected by routine use of a post-procedural bivalirudin infusion at 1.75 mg/kg/h for 3 to 4 h post-PCI, which may eliminate the excess acute risk of ST without increasing bleeding (19) (20) (21) .
Similarly, intensification of P2Y 12 -receptor inhibition with intravenous cangrelor compared with clopidogrel during the PCI procedure and for the first 2 to 4 h thereafter favorably reduces the acute and 48-h rates of MI and ST without increasing major bleeding (22) .
In contrast, although the use of prasugrel rather than clopidogrel in patients with acute coronary syndromes (ACSs) was highly effective in reducing adverse ischemic events early after PCI, the excessive bleeding complications with this irreversible agent Giustino et al. non-CABG-related major bleeding (26) . Of note, the benefits of ticagrelor in this trial did not begin to emerge until several weeks after initiation, and they continued to diverge throughout the 1-year follow-up period, as predicted from the present study (26) .
Thus the current analysis confirms current guidelines supporting consistent and high-intensity platelet inhibition to $1 year after primary PCI in STEMI, thereby emphasizing the selection of agents and consideration of patients' comorbidities to ensure an optimal balance of ischemia suppression and bleeding risk (27) .
The insights from the present study may also have bearing on the design of future randomized controlled trials for primary or secondary prevention in patients with ACS and in patients undergoing PCI.
In particular, inclusion of recurrent events (i.e., Least square mean differences (LSMD) between the average daily ischemic and bleeding rates in the acute, subacute, early, and late periods. The x-axis displays time.
The y-axis displays the LSMD between ischemia and bleeding, with LSMD >1 if ischemia exceeds bleeding and LSMD <1 if bleeding exceeds ischemia. In the early period (before 30 days), the rates of bleeding exceed those for ischemia. In the late period (from 30 days to 1 year), the average daily ischemic rate (ADIR) significantly exceeds the average daily bleeding rate (ADBR). CI ¼ confidence interval; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction. 
